Citation Impact
Citing Papers
IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Stromal fibroblasts in cancer initiation and progression
2004 StandoutNature
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
A view on drug resistance in cancer
2019 StandoutNature
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Hepatocellular carcinoma
2018 Standout
Role of Transforming Growth Factor β in Human Disease
2000 Standout
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Vascular endothelial growth factor receptor‐1 in human cancer
2010
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses
2014
TGF-β signalling from cell membrane to nucleus through SMAD proteins
1997 StandoutNature
Genetic instabilities in human cancers
1998 StandoutNature
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
2016
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
2015
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
The Hallmarks of Cancer
2000 Standout
An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
2011
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Transforming growth factor-β induces development of the TH17 lineage
2006 StandoutNature
Diversity of the Immunoglobulin Gene Superfamily
1989
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
2015
HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation
2003 Standout
Potent Prostaglandin A1 Analogs That Suppress Tumor Cell Growth through Induction of p21 and Reduction of Cyclin E
1998 StandoutNobel
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
AUTOCRINE AND PARACRINE REGULATION BY CYTOKINES AND GROWTH FACTORS IN MELANOMA
2000
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
1994 StandoutNature
G1 phase progression: Cycling on cue
1994 Standout
Regulatory T cells in transplantation tolerance
2003 StandoutNobel
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Genetic alterations in leukemias and lymphomas: Impressive progress and continuing complexity
1997
Principles of CDK regulation
1995 StandoutNature
Gastric cancer
2020 Standout
Pancreatic Cancer
2010 Standout
Cyclin-Dependent Kinase Regulation during G1 Phase and Cell Cycle Regulation by TGF-ß
1997
Modulation of Leukocyte Behavior by an InflamedExtracellular Matrix
2000
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
1994 Standout
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
2000 Standout
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Tumor Angiogenesis
2008 Standout
Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
2008
Limited diversity of γδ antigen receptor genes of thy-1+ dendritic epidermal cells
1988 StandoutNobel
Tumor suppressor activity of the TGF-β pathway in human cancers
1996
Transforming Growth Factor-β and Breast Cancer Risk in Women With Mammary Epithelial Hyperplasia
1999
Hepatocellular Carcinoma
2019 Standout
IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor
2007
Naturally Arising CD4+Regulatory T Cells for Immunologic Self -Tolerance and Negative Control of Immune Responses
2003 StandoutNobel
Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
2013
TGF-β SIGNAL TRANSDUCTION
1998 Standout
Immunochemical Proof That a Novel Rearranging Gene Encodes the T Cell Receptor δ Subunit
1987 Science
Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males
2007 StandoutNobel
Limited diversity of T-cell receptor gamma-chain expression of murine Thy-1+ dendritic epidermal cells revealed by V gamma 3-specific monoclonal antibody.
1989 StandoutNobel
The Type 1 Insulin-Like Growth Factor Receptor Pathway
2008
Cancer Cell Cycles
1996 StandoutScience
Lack of a role for transforming growth factor-β in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation
2001 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
A Dominant Inhibitory Mutant of the Type II Transforming Growth Factor β Receptor in the Malignant Progression of a Cutaneous T-Cell Lymphoma
1996
Calcitonin Gene-Related Peptide Decreases Expression of HLA-DR and CD86 by Human Dendritic Cells and Dampens Dendritic Cell-Driven T Cell-Proliferative Responses Via the Type I Calcitonin Gene-Related Peptide Receptor
2000 StandoutNobel
Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies
2004
CD28 disruption exacerbates inflammation in Tgf-β1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-β1
2004 StandoutNobel
The retinoblastoma protein and cell cycle control
1995 Standout
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
2000
TGF-β Mediates CTLA-4 Suppression of Cellular Immunity in Murine Kalaazar
2000
Structural design and molecular evolution of a cytokine receptor superfamily.
1990 Standout
Dendritic cells are specialized accessory cells along with TGF-β for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3− precursors
2007 StandoutNobel
Vascular Actions of Calcitonin Gene-Related Peptide and Adrenomedullin
2004
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
A Deletion in the Gene for Transforming Growth Factor β Type I Receptor Abolishes Growth Regulation by Transforming Growth Factor β in a Cutaneous T-Cell Lymphoma
1999
Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen.
1995
TGF-β1 Uses Distinct Mechanisms to Inhibit IFN-γ Expression in CD4+ T Cells at Priming and at Recall: Differential Involvement of Stat4 and T-bet
2005
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
The two faces of transforming growth factor β in carcinogenesis
2003 Standout
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
1996 StandoutScience
A Role for TGF-β in the Generation and Expansion of CD4+CD25+ Regulatory T Cells from Human Peripheral Blood
2001
Transforming growth factor β and cancer
1995
Works of Floyd E. Fox being referenced
Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors
2007
A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis
2007
Calcitonin Gene-Related Peptide Inhibits Proliferation and Antigen Presentation by Human Peripheral Blood Mononuclear Cells: Effects on B7, Interleukin 10, and Interleukin12
1997
Evidence That TGF-β Can Inhibit Human T-Lymphocyte Proliferation through Paracrine and Autocrine Mechanisms
1993
Induction of metalloproteinase activity in human T-lymphocytes
1993
Photoactivated Hypericin is an Anti-Proliferative Agent that Induces a High Rate of Apoptotic Death of Normal, Transformed, and Malignant T Lymphocytes: Implications for the Treatment of Cutaneous Lymphoproliferative and Inflammatory Disorders
1998
Differential Effects of Human Alpha and Gamma Interferons on Mixed Lymphocyte Culture and on T-Cell-Mediated Cytotoxicity
1988
Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sézary patients.
1995
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
2010
Regulation of cytokine expression in macrophages and the Langerhans cell-like line XS52 by calcitonin gene-related peptide
1997
Identification of a second T-cell antigen receptor in human and mouse by an anti-peptide gamma-chain-specific monoclonal antibody.
1987
A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
2003
406 POSTER IMC-18F1, a recombinant human monoclonal antibody (MAb) against the vascular endothelial growth factor receptor-1 (VEGFR-1), in the treatment of patients (pts) with advanced solid malignancies: A Phase 1 study
2008
Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells.
1994
A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors
2007
A phase II multicenter study of cetuximab monotherapy in patients with EGFR-undetectable refractory metastatic colorectal carcinoma (mCRC)
2008
A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
2010
Transforming growth factor-beta inhibits human T-cell proliferation through multiple targets.
1992
648 POSTER A phase I dose-escalation study of weekly IMC-A12, a fully human insulin like growth factor-I receptor (IGF-IR) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer
2006